131 I ablation is considered an effective and safe adjuvant therapy modality for differentiated thyroid cancer (DTC), although there is an ongoing debate about the need for 131 I ablation in patients without lymph node or distant metastases and with low stages of the primary (pT1-2) tumor. However, on the basis of evidence from retrospective studies and pending the results of ongoing controlled prospective randomized trials, it seems advisable to perform 131 I remnant ablation in patients with primary tumors [1 cm. For thyroid remnant ablation, individual dosimetry is not generally considered necessary, but it may improve success rates if used according to strict criteria. The use of recombinant human TSH (rhTSH) for patient preparation allows maintenance of quality of life and results in a lower radiation exposure of healthy non-thyroid tissue compared with TSH stimulation through levothyroxine withdrawal. This approach has been approved for 131 I ablation, but not for 131 I therapy of distant metastases.
Introduction
Treatment of differentiated thyroid cancer (DTC) usually consists of a combination of surgery, 131 I treatment, and thyroid hormone administration aiming to obtain, depending on the disease stage, TSH levels in the low-normal range or TSH suppression [1] [2] [3] [4] [5] . Although different guidelines have tried to establish consensus on aspects of DTC diagnosis and treatment [1] [2] [3] [4] 6] , the extent to which the aforementioned treatment modalities should be used in patients with different stages of DTC at diagnosis is an issue that continues to be debated. In low-risk DTC patients, in particular, this debate concerns, for example, the appropriate extent of tumor and lymph node surgery, the indications for 131 I ablation after surgery, and the need for TSH suppression through high dosages of levothyroxine in the early post-operative phase of follow-up.
Specifically, there are many open questions about the effectiveness of 131 I thyroid remnant ablation, the activity of 131 I that should be used, and the use of recombinant human TSH (rhTSH) for preparation of patients prior to 131 I ablation. This review sets out to answer some of these questions taking into account recently published evidence and new insights into the treatment [7] and (re)staging of DTC.
clearly showed that the rates of both recurrence and death related to DTC were much lower in patients who had been treated with additional 131 I ablation after surgery than in those who did not receive 131 I. Accordingly, we recently found evidence that patients consistently treated with postoperative 131 I ablation-with the exception of those in advanced disease stages (i.e., extensive local invasion, lateral lymph node metastases, or distant metastases; comprising TNM stages IVa-IVc)-had a normal life expectancy [9, 10] . Previously, we had already shown that successful 131 I thyroid remnant ablation was a clear early predictor of this favorable prognosis [11, 12] .
A main reason for the good prognosis of DTC is the use of 131 I in both ablative and therapeutic settings. 131 I-NaI comes close to being the ideal cancer theranostic drug: it emits therapeutically useful beta radiation as well as gamma rays suitable for imaging the drug distribution, and it can be used both for diagnostics and for treatment. 131 I has limited side effects and is a highly specific radiopharmaceutical for targeting cancer cells that have retained the thyroid cells' normal attributes as the body's main iodine reservoir and primary locus of expression of the sodiumiodide symporter (NIS) [13] .
Most current guidelines recommend postsurgical application of a high ('ablative') 131 I activity as a second component of the primary treatment of DTC in some or most (near) totally thyroidectomized patients [1] [2] [3] [4] .
In clinical practice, 131 I ablation has three goals [14]:
• To destroy occult small DTC foci, thereby decreasing the long-term risk of recurrent disease [8, 11, 15- Figure 1 shows an example of such findings and their successful treatment. In selected cases, post-ablation scintigraphy also allows precise surgical or even probeguided removal of the newly detected disease foci [23] .
Achieving these goals is supposed to lead to decreased rates and earlier diagnosis of persistent or recurrent disease and, more importantly, to improve cancer-specific survival in thyroidectomized DTC patients [8, 17, 24] . The absence of evidence of such beneficial effects in DTC patients with very low-risk microcarcinoma (B1 cm diameter, without local invasion or metastases in the absence of unfavorable histology) has, for years, led to a generally accepted policy of not performing 131 I ablation in these patients. Given that evidence on the possibility of 131 I-induced second primary tumors is conflicting, which effectively means that, especially in younger patients, the risk of inducing such second primary tumors cannot be ruled out, the balance between the potential risks and benefits of 131 I ablation in very lowrisk patients is such that, in most cases, this procedure should be advised against.
The beneficial effects of 131 I ablation may partly depend on the completeness of the surgical thyroidectomy: complete excision of all thyroid tissue by the most highlyskilled surgeons may obviate the need for ablation at least in low-risk cases [25] .
There is, in fact, considerable debate over the question of which patients actually require 131 I ablation. Survival benefits of this procedure have not been unequivocally Fig. 1 Ventral post-therapy (left) and 6 months post-ablation diagnostic (right) ventral whole-body scans of a patient with a postoperative thyroid remnant and remaining lateral lymph node metastases. It can be seen that ablation was a complete success demonstrated for low-risk patients (TNM stage T1-2N0M0), and the measured effects on the prevention of recurrent disease differ between studies [26, 27] . In patients with a non-invasive primary tumor \2 cm in diameter, no significant difference can be found in remission or death rates between those who did and those who did not receive 131 I ablation [28] . This may, however, be partially due to the inherently good prognosis and to the extremely long follow-up required to see any statistical effects; generally, in the literature, it appears that the longer the follow-up of a study, the more likely it is to show a significant benefit of 131 I ablation in terms of recurrence-free and disease-specific survival in the total DTC population [26, 29] . In view of the natural course of thyroid cancer, it is also necessary to consider the possibility of using alternative outcome measures to deduce a significant effect of 131 I therapy. A meta-analysis by Sawka et al. [29] found a significantly lower risk for developing distant metastases after 131 I ablation in patients with a tumor diameter [1 cm, which indicates that a significant benefit from 131 I ablation can be obtained even in patients who are traditionally considered to be low-risk. However, other meta-analyses by Sawka et al. [30] and Subramanian et al. [31] also found a slightly increased risk of developing second primary malignancies in patients after 131 I ablation compared to DTC survivors who did not receive 131 I. Therefore, the balance between the benefits and the risks of 131 I ablation in low-risk patients has yet to be determined.
As a result of the debate over the possible benefits of 131 I ablation in low-risk patients, the decision on whether this procedure is actually carried out is influenced by many factors other than national and international guidelines; these include access to an interdisciplinary tumor board, the presence in a single institution of surgery, endocrinology and nuclear medicine departments, and the specialty of the primary decision maker in a patient's care [32] .
Instead, the beneficial effects of initial 131 I therapy have clearly been shown in high-risk patients and in cases of non-radical surgery [8, 33, 34] .
Standard activities versus individual dosimetry
Today, over 70 years [35] after the first treatment of DTC by systemic administration of radioiodine, there is still no generally accepted dosage regimen to ensure an individually optimized therapy.
Standard activities
The radioiodine therapy method most often used is administration of a standard activity of 131 I, and empirical variation of this fixed activity dosage is the simplest way of optimizing the therapy. There is consensus in current guidelines that the primary goal of 131 I therapy, i.e., thyroid remnant ablation as an adjuvant modality after thyroidectomy or as therapy (curative or palliative) of local tumor and distant metastases, should influence the therapeutic activity used [1, 2, 4] .
Many studies have been undertaken to identify the optimum activity to administer, especially for thyroid remnant ablation, and the search is still going on. Doi and Woodhouse [36] reviewed 19 studies comparing the efficacy of high versus low ablation activities and pooled data of 11 of these in a meta-analysis together with their own cohort study data. They concluded that treatment with high-dose 131 I is significantly more efficient for remnant ablation, particularly after less than total thyroidectomy. In a more recent systematic review, Hackshaw et al. [37] performed a meta-analysis of data from 41 patient case reviews, 12 prospective studies, and six randomized trials published between 1966 and 2006 and concluded that the current evidence is not conclusive and that published data are insufficient to reliably determine whether ablation success rates are similar with ablation activities of 1.1 versus 3.7 GBq. However, a re-analysis of the same data as used in [37] led Doi et al. [38] to the opposite conclusion: they found a significant difference between the efficacies of the tao regimens. Cheng et al. [39] more recently found that there was no difference in ablation success rates between lower and higher activities. These differing results show that this subject remains controversial and current guidelines leave it up to the physician in charge of the case to select a radioiodine activity of between 1.1 and 3.7 GBq for postsurgical ablation of thyroid residues.
Recently, two very similar major trials comparing 1,110 and 3,700 MBq 131 I for thyroid remnant ablation were reported, one from Great Britain (HiLo) and the other from France (NCT0043585; ESTIMABL) [40, 41] . According to these trials, 1,110 and 3,700 MBq are equally effective for 131 I remnant ablation in low-risk thyroid cancer patients, and the use of rhTSH in preparation for this procedure is as effective as thyroid hormone withdrawal (THW), with both activities. However, these trials present several problems. The first problem concerns the criteria used to determine successful ablation, which have a decisive influence on the observed rates of success. Both trials considered Tg (serum Tg is a tumor marker), applying cut-off levels of 1 or 2 ng/ ml, which is an order of magnitude higher than the functional sensitivity of modern immunoassays. In fact, it was recently shown any patient with detectable disease is likely to develop a Tg at such a random threshold [42] . The French study did not generally assess the completeness of ablation by 131 I diagnostic whole-body scintigraphy in patients without antibodies against Tg, thus opening up the possibility that remaining thyroid remnants could have been classified as successful ablations. Furthermore, in those cases in which diagnostic whole-body scintigraphy was performed due to the presence of such antibodies, ablation was considered successful in patients with an uptake of \0.5 % of the administered activity-which is much higher than in previous studies on the subject [43] and also well in excess of any threshold that would be taken as positive on visually assessed scans [44] . Also, once again, especially in the case of the French study, it is doubtful whether 131 I ablation was indicated in many of the patients, considering that a large proportion of those included were operated upon in a center of thyroid surgical excellence resulting in a Tg level that was already undetectable before 131 I ablation, likely indicating that complete thyroid remnant ablation had already been achieved through surgery alone. However, especially in the case of the French study, the better quality of the surgery and the less stringent criteria for defining successful ablation make for a questionable combination. Lower 131 I activities will nearly always suffice to achieve ablation [45] when surgery has been good. As the criteria for successful ablation in the above studies are much less strict than in much of the previous literature, any differences in ablation rates that might have argued in favor of higher activities are blurred. Furthermore, it is uncertain whether successful ablation, defined according to these criteria, is still a good indicator of prognosis. A follow-up period of several years will be required to assess the recurrence rate in the various subgroups in these trials before a definitive judgment on the activity and mode of stimulation can be made.
In the light of these concerns, the same groups have now initiated prospective studies on the need for 131 I ablation [46] . Even though prospective evidence now exists to support the choice of activity in low-risk patients, there still remains a large gap in the evidence surrounding the choice of activity for 131 I ablation in high-risk patients-here empirical activities will likely remain the norm for a long time to come.
Dosimetry
In 131 I ablation, there are several parameters that, in relation to the radiation absorbed dose to the target tissue, are just as important as administered activity and possibly even more so. Iodine avidity, which depends on, for example, the degree and duration of TSH stimulation as well as the differentiation of DTC tissue, the residence time of the radioiodine per volume of blood plasma (representing the bioavailability of the 131 I), the effective half-life in the target volume, and the mean energy deposited per decay, which is mainly determined by size and shape of the accumulating mass [47] , all play important roles in the eventual determination of the radiation absorbed dose to the target tissue. The fact that all these parameters [47] show high interindividual variations fundamentally calls into question the value and feasibility of the quest for the ''best'' fixed therapeutic activity, as no fixed activity will be able to adequately compensate for these variations.
Furthermore, multiple administrations of lower activities in a ''fractionated'' therapy may lead to changes in tumor/ lesion biokinetics [48, 49] . These findings suggest that repeated treatment of a lesion drastically reduces its uptake as the least radioiodine-avid cells are more likely to remain unaffected when a submaximal activity of 131 I is administered, resulting in a loss of therapeutic efficacy over the course of therapy cycles. Therefore, administration of a single, high 131 I activity is likely to be more effective than the same activity delivered cumulatively over multiple administrations.
To overcome the uncertainty over individual biokinetics, two dosimetry-based approaches have been introduced by Benua et al. and Maxon et al. In 1962, Benua et al. [50] used the easily measurable absorbed dose to the blood as a conservative estimate of the absorbed dose to the red bone marrow (the dose-limiting organ), and found a limit of 2 Gy to be associated with the highest activity that is safely administrable to the individual without severe damage to the hematopoietic system. This limit of 2 Gy absorbed dose to the blood was, however, based on only a few cases of severe bone marrow suppression [50] . The results of a study applying a 3-Gy red marrow dose [51] together with the observation that patients treated with fixed activities of 7.4 or 11.1 GBq frequently exceed Benua's safety limit [52, 53] , while none of these studies report corresponding cases of severe hematotoxic reactions, seem to indicate that the 2 Gy limit is probably conservative. The blood dose closely reflects the true amount of 131 I available to the target tissue [54] . In 131 I thyroid remnant ablation, the blood dose seems to correlate better with success of ablation than the administered activity alone [45, 55] . Later, Maxon et al. [56, 57] reported an approach which aimed to achieve a specific radiation absorbed dose to the target tissue, namely 300 Gy to thyroid remnants and 80 Gy for the treatment of cervical lymph node metastases. Although these values have since been quoted often and used widely, they have not been verified prospectively. In Maxon's lesion dosimetry approach, the recommended values suffer from uncertainties regarding the determination of the target mass and how much of the energy is imparted to surrounding tissue. This is always a challenging question in the case of small and irregularly shaped tissues. More recent studies based on measurements obtained using improved equipment support the hypothesis that success of ablation correlates with the absorbed dose administered to the target tissue [58] , but do not generally confirm the values established by Maxon.
The main argument against Maxon's approach stems from the fact that absorbed doses may vary considerably between different lesions within the same patient and that the distribution of the absorbed dose in a tumor may be inhomogeneous, as shown by studies using 124 I [49, 59] . This may lead to under-treatment of lesions not included in the dosimetric evaluation or with supposedly sufficient absorbed dose but inhomogeneous activity distribution. Prospective studies are needed to clarify whether or not improved techniques for dosimetry which are now available in the form of PET/CT with 124 I [60] and the introduction of formalisms to weigh the measurements, such as the calculation of the biologically effective dose or the equivalent uniform dose [61, 62] , will result in unique and reliable recommendations for lesion dosimetry in DTC.
Patient preparation
Low-iodine diet A low-iodine diet for 2-3 weeks before radioiodine administration aiming to restrict iodine intake to \50 lg per day is strongly recommended [63] [64] [65] ; even more important is the avoidance of iodine-containing drugs (e.g., X-ray contrast media, reagents for disinfection, ophthalmologic agents, amiodarone, iodide medication) and food or food additives with a high iodine content (e.g., seaweed, kelp, dietary supplements) [1] .
Determination of iodine excretion using spot urine samples may be a useful way to identify patients whose stable iodine load could interfere with radioiodine uptake.
TSH stimulation 131 I ablation of supposedly benign postsurgical thyroid remnants is considered to demand serum thyrotropin levels above 30 mU/l to induce sufficient uptake in ''healthy'' thyroid or tumor tissue [1, 2, 4] . This ''TSH stimulation'' can be induced by THW for some weeks or, alternatively, exogenously by i.m. injections of rhTSH. The advent of rhTSH made it possible to achieve sufficiently high TSH levels without the need for a period of sometimes debilitating clinical hypothyroidism. Developed by Weintraub et al. [66] , rhTSH was initially licensed for use with follow-up diagnostic whole-body scanning (dxWBS) and serum Tg testing [67] . The advantages of rhTSH include prevention of the sometimes severe morbidity associated with hypothyroidism after THW [68] and an unimpaired quality of life [69] [70] [71] .
In addition, rhTSH allows a lower radiation exposure to the rest of the body, including the bone marrow, due to a substantial decrease (-35 % on average) in circulating 131 I in the blood [47] . This latter finding must be attributed to preserved renal 131 I clearance in euthyroid conditions [47, 72] . A decreased whole-body radiation exposure implies, in theory at least, a lower risk for secondary cancers after radioiodine therapy. Recent studies also demonstrated a favorable ''radiation profile'' for other organs at risk, such as the reproductive system and the salivary glands [73, 74] .
In addition to showing a superior profile in terms of the spectrum of potential side effects, the various outcome data for the modern approach of exogenous rhTSH administration are of great importance, with studies showing equivalent results. Data on almost 600 patients, reported in several uncontrolled studies and two randomized controlled trials, show that rhTSH stimulation for thyroid remnant ablation is successful in about 80-90 % of patients, comparable to rates seen with THW preparation [75] . In fact, in the recent HiLo and ESTIMABL studies, each of which recruited many hundreds of patients, rhTSH was as effective as THW for reaching the main outcome criteria for successful ablation, even at low activity (1,110 MBq, or 30 mCi) [40, 41] . In both studies, ablation rates of around 90 % were seen with both rhTSH and THW. Nonetheless, the number of patients studied in randomized controlled trials comparing THW with rhTSH for ablation is low in relation to the number of patients treated worldwide each year; this is especially true of highrisk patients, as most studies on rhTSH tend to include more low-risk patients. There are no trials in the literature in which THW was compared with rhTSH for the treatment of metastasized disease and until this gap in current knowledge is filled; we would advise against using rhTSH in such patients when withdrawal is a medically and psychologically feasible option, given that, in theory at least, the prolonged stimulation of DTC cells during withdrawal might lead to a higher tumor absorbed dose compared to rhTSH.
A randomized prospective phase III study in mainly low-risk patients proved that a standard activity of 3.7 GBq 131 I led to comparable ablation rates of approximately 90 % both after THW and after rhTSH. These results were achieved when successful ablation was defined as the combination of radioiodine neck uptake \0.1 % on a dxWBS and of serum Tg \2 ng/ml under rhTSH stimulation at 8 ± 1 months after ablation [43] . In the meantime, the mid-to long-term follow-up of patients enrolled in this prospective trial proved the comparable efficacy, in preventing disease recurrence, of radioiodine ablation following preparation with rhTSH as compared to withdrawal [76] .
In a retrospective analysis from the Memorial SloanKettering Cancer Center [77] which investigated almost 400 patients, including a higher risk study population with locally advanced (T3 and some T4) tumors, it was found that rhTSH-and withdrawal-aided ablation were associated with low rates (not statistically different) of clinical recurrence or persistent thyroid bed uptake, as well as with a statistically similar time to recurrence. This led the American Thyroid Association [1] , the European Society of Medical Oncology [3] , and the European Association of Nuclear Medicine [4] to recommend preparation of radioiodine ablation with rhTSH as the method of choice because of its equal efficacy but lower rate of side effects.
However, it has to be stressed that the approval for use of rhTSH does not extend to patients suffering from distant metastases and that the compassionate use of rhTSH in such patients should be limited to clinical situations that are not otherwise manageable, e.g., elderly and frail patients. Although the number of reports on the treatment of advanced disease under rhTSH is steadily increasing this remains an off-label use [78] [79] [80] .
Compared to ''conventional'' treatment options with a similar cost-effectiveness ratio, rhTSH in the ablation setting appears to be cost-effective according to value-based drug purchasing [81, 82] . Model calculations obtained in a study by Mernagh et al. [83] , which adopted a societal perspective, showed that the use of rhTSH rather than THW led to a gain of 0.05 quality adjusted life years (QALYs) per course, which was attributable to a reduction of missed work time and a calculated lower rate of secondary malignancy. The additional cost associated with this increase in QALY, calculated as an incremental cost-effectiveness ratio (ICER), amounted to 958 €/QALY, which, in view of the generally accepted ICER threshold of 45,000 €/QALY for new interventions suggests that preparation of ablative radioiodine therapy by rhTSH is cost-efficient.
Aside from gains in quality of life, it is necessary to consider other advantages that are not easily captured in modeling, such as more convenient scheduling of patients.
Some institutions, when using exogenous TSH stimulation advocate ''mini-withdrawal'' of levothyroxine a few days before the two rhTSH injections and a few days after radioiodine administration, to reduce the intake of stable iodine provided by thyroid hormone medication (100 lg of levothyroxine contains approximately 65 lg of iodide) [84] . A study by Barbaro et al. [85] compared urinary iodine excretion after rhTSH stimulation and continued T4 medication versus rhTSH stimulation and thyroid hormone ''mini-withdrawal''. Iodine excretion was found to be significantly lower after ''mini-withdrawal'' (47.2 ± 4.0 versus 76.4 ± 9.3 lg/l, p = 0.019). The ablation success rate after 1 year was slightly higher after rhTSH-aided ablation with short-term THW compared to stimulation with traditional THW (81.2 versus 75.0 %). In contrast, Tala Jury et al. [86] were not able to find a relationship between urinary iodine excretion and the success rate of rhTSHaided ablation.
Conclusions
More than 70 years after the first 131 I treatment of DTC, a number of questions remain, related to 131 I ablation indications, preparation, and treatment protocol. Over the past decade, some key issues, such as the indication for 131 I ablation in low-risk patients, individual dosimetry, and preparation for 131 I ablation by rhTSH, have been addressed more systematically; nonetheless, question marks remain even over seemingly solid prospective data.
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